KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).J Clin OncolPMID 35446628PMC95533902022-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.Int J CancerPMID 35489024PMC95454402022-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.J Clin OncolPMID 35584336PMC95533882022-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial.Ann SurgPMID 35866644无 PMCID2022-Oct-010.90The study is a Phase III randomized trial in human oncology with a primary time-to-event endpoint (DFS), but the intervention is a follow-up strategy, not a drug-containing regimen as required for inclusion.待处理
Ultrasound-guided selective trunk block: Evaluation of ipsilateral sensorimotor block dynamics, hemidiaphragmatic function and efficacy for upper extremity surgery. A single-centre cohort study.Eur J AnaesthesiolPMID 35950709无 PMCID2022-Oct-010.98未发现恶性肿瘤人群证据。待处理
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.JAMA OncolPMID 35980649PMC93894402022-Oct-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.LancetPMID 36099926无 PMCID2022-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.Br J OphthalmolPMID 34001667PMC95104092022-Oct0.98未发现恶性肿瘤人群证据。待处理
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.J Eur Acad Dermatol VenereolPMID 35460287PMC95456142022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.Br J DermatolPMID 35553043PMC97962772022-Oct0.98未发现恶性肿瘤人群证据。待处理
Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.J Intern MedPMID 35599154PMC93475702022-Oct0.98未发现恶性肿瘤人群证据。待处理
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.Diabetes Obes MetabPMID 35670659PMC95460642022-Oct0.98未发现恶性肿瘤人群证据。待处理
The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.J Cancer Res Clin OncolPMID 35672525PMC118009372022-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.Clin RheumatolPMID 35676450无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Respir MedPMID 35688164PMC91737212022-Oct0.98未发现恶性肿瘤人群证据。待处理
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.J Am Acad DermatolPMID 35714786无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials].Strahlenther OnkolPMID 35732920无 PMCID2022-Oct0.85While the record meets criteria for oncology, human, randomized, Phase III, and original result, it lacks explicit evidence of a drug intervention and a time-to-event efficacy endpoint from the provided metadata. Therefore, it is not eligible.待处理
A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.Allergol IntPMID 35752582无 PMCID2022-Oct0.95The study is a randomized, double-blind, Phase III trial evaluating the safety and efficacy of gefapixant for chronic cough (refractory or unexplained), which is a non-oncological condition. While it meets criteria for human, randomized, Phase III, drug intervention, and original results, it is excluded because it is not an oncology study and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints reported are safety, tolerability, and quality of life, not the required time-to-event efficacy outcomes.待处理
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study.Bone Marrow TransplantPMID 35768571PMC95322402022-Oct0.85The record is from a randomized Phase III trial in oncology (multiple myeloma) and includes a drug intervention (cyclophosphamide). However, the specific report is an exploratory, post-hoc analysis of genetic variants in relation to patient-reported quality of life and pain, not a primary efficacy result. It lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR).待处理
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.Mult SclerPMID 35768939PMC94426302022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.ESC Heart FailPMID 35794067PMC97158652022-Oct0.98未发现恶性肿瘤人群证据。待处理
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.Lancet Respir MedPMID 35817072PMC92700592022-Oct0.98未发现恶性肿瘤人群证据。待处理
Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.Radiother OncolPMID 35817320无 PMCID2022-Oct0.95The study is a Phase II randomized trial in oncology with human patients and includes time-to-event efficacy endpoints (LRRFS, DMFS, OS). However, it is ineligible because it is Phase II (not Phase III/IIIb) and the intervention is a radiation technique (SPLS-IMRT vs C-IMRT), which is a non-drug intervention. The primary endpoint is xerostomia incidence, not a time-to-event efficacy endpoint. The deterministic review correctly flagged insufficient drug intervention evidence.待处理
Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.Eur UrolPMID 35902289无 PMCID2022-Oct0.55The record is a Phase III randomized trial with a time-to-event endpoint (DFS) in human prostate cancer. However, the abstract is empty and the provided metadata (including the deterministic review's 'drug_intervention: false' signal) does not contain explicit evidence that a systemic drug intervention was part of the trial's control or experimental arms. The trial involves 'Androgen Deprivation' which could be a drug intervention (e.g., androgen antagonists), but this is not explicitly confirmed as a drug-containing intervention in the provided data. Therefore, eligibility cannot be confirmed.待处理
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.Eur J CancerPMID 35922251无 PMCID2022-Oct0.95This is a primary report of a Phase III randomized trial in oncology with a drug intervention, but the explicitly reported primary/key secondary endpoints are patient-reported quality-of-life and functioning outcomes (EORTC QLQ-C30 scales), not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The 'time to definitive deterioration' mentioned is a time-to-event analysis of patient-reported outcomes, not a traditional oncological efficacy endpoint.待处理
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.Lancet Respir MedPMID 35926542无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.Calcif Tissue IntPMID 35927518无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.Adv TherPMID 35947347PMC94647382022-Oct0.98未发现恶性肿瘤人群证据。待处理
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.LeukemiaPMID 35963941无 PMCID2022-Oct0.45The record is a secondary biomarker analysis from a Phase III randomized trial. While it meets criteria for oncology, human, randomized, phase3, drug intervention, and is an original result, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) and associated statistics (Kaplan-Meier, HR) for the primary/key secondary endpoint. The deterministic review correctly identified the absence of a time-to-event signal.待处理
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.Clin Transl SciPMID 35986664PMC95793812022-Oct0.98未发现恶性肿瘤人群证据。待处理
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.Int J Infect DisPMID 35987467无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.ESMO OpenPMID 35994789PMC95888982022-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.Mult Scler Relat DisordPMID 36007339无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study.Clin TherPMID 36030106无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.CPT Pharmacometrics Syst PharmacolPMID 36047474PMC95747452022-Oct0.98未发现恶性肿瘤人群证据。待处理
Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm.Lung CancerPMID 36058174无 PMCID2022-Oct0.90The study is a Phase III randomized trial with primary time-to-event endpoints (OS, DFS) for human oncology, but it compares surgical procedures and does not include a drug-containing intervention as required by the criteria.待处理
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.Eur J CancerPMID 36067615无 PMCID2022-Oct0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.Lancet OncolPMID 36075260无 PMCID2022-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.Drugs AgingPMID 36098936PMC95537782022-Oct0.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.Lancet OncolPMID 36108662无 PMCID2022-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients.Clin TherPMID 36182594无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.HeadachePMID 36239038PMC98278202022-Oct0.98未发现恶性肿瘤人群证据。待处理
A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.Clin TherPMID 36241463无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO).Int AngiolPMID 36264097无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.HeadachePMID 36286602无 PMCID2022-Oct0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.DrugsPMID 36287379PMC96077002022-Oct0.98未发现恶性肿瘤人群证据。待处理
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.Health Technol AssessPMID 36300825PMC96392192022-Oct0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.Clin Infect DisPMID 35165682PMC95250902022-Sep-300.98未发现恶性肿瘤人群证据。待处理
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.Clin Infect DisPMID 35148378PMC95223952022-Sep-290.98未发现恶性肿瘤人群证据。待处理
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.JAMAPMID 36166026PMC95163232022-Sep-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理